Evidence map›Paper›PMID 42500934›Full record

ArticleAdvanced healthcare materials2026

Patient-Derived 3D Heart-On-a-Chip Model of Dilated Cardiomyopathy With Embedded Bead-Based Mapping of Tissue Contractility.

Ali Mousavi, Ludovic Mouttet, Shihao Cui, Yasaman Hekmatnia, Mehran Mottahedi, Ida Derish, Naimeh Rafatian, Mark Aurousseau, Gregor Andelfinger, Renzo Cecere and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ali MousaviInstitute of Biomedical Engineering, Department of Pharmacology and Physiology, Faculty of Medicine, Université De Montréal, Montréal, QC, Canada.ORCID https://orcid.org/0009-0007-0542-4995
Ludovic MouttetResearch Institute of the McGill University Health Centre, Montréal, QC, Canada.ORCID https://orcid.org/0009-0001-8084-8823
Shihao CuiCHU Sainte-Justine Research Center, Montréal, QC, Canada.
Yasaman HekmatniaResearch Institute of the McGill University Health Centre, Montréal, QC, Canada.ORCID https://orcid.org/0000-0002-0785-5285
Mehran MottahediResearch Institute of the McGill University Health Centre, Montréal, QC, Canada.ORCID https://orcid.org/0000-0003-0406-8670
Ida DerishResearch Institute of the McGill University Health Centre, Montréal, QC, Canada.
Naimeh RafatianCHU Sainte-Justine Research Center, Montréal, QC, Canada.ORCID https://orcid.org/0000-0003-1240-1568
Mark AurousseaueNUVIO Inc., Montréal, QC, Canada.
Gregor AndelfingerCHU Sainte-Justine Research Center, Montréal, QC, Canada.
Renzo CecereResearch Institute of the McGill University Health Centre, Montréal, QC, Canada.
Houman SavojiInstitute of Biomedical Engineering, Department of Pharmacology and Physiology, Faculty of Medicine, Université De Montréal, Montréal, QC, Canada.ORCID https://orcid.org/0000-0002-5596-673X

Funding

Courtois Cardiovascular Signature ProgramEstablishment of Young Investigators, FRQS 324277Fonds de Recherche du Québec Santé (FRQS) 313837Montreal TransMedTech Institute (iTMT)Natural Sciences and Engineering Research Council of Canada DGECR-2021-00337Natural Sciences and Engineering Research Council of Canada RGPIN-2021-03960Research Center of CHU Sainte-Justine (CRCHUSJ)ThéCell Structuring Project GrantUniversity of Montreal, Polytechnique MontrealWellcome Trust 324277
6 · The paper itself

Abstract

Dilated cardiomyopathy (DCM) is the leading cause of heart transplantation, with a 50% risk of progression to heart failure within 5 years. Conventional disease modeling approaches fail to recapitulate the sophisticated function of the human heart. Alternatively, heart-on-a-chip (HOC) platforms enable real-time monitoring of disease progression and drug responses using miniaturized engineered heart tissues. Here, we developed a functional HOC model using patient-specific human induced pluripotent stem cells (hiPSCs), reprogrammed from the patients' blood samples. The chip contains two cell-seeding chambers with flexible silicone pillars to support tissue formation. Healthy and DCM hiPSCs were differentiated into cardiomyocytes, combined with an optimized ratio of human cardiac fibroblasts, encapsulated in a fibrin/Geltrex hydrogel (containing fluorescent beads), and seeded in the device chambers. The tissue gradually compacted and started beating spontaneously. Immunofluorescence assay revealed structural abnormalities in DCM tissues, including reduced cell alignment and elongation. The tissue functional responses (e.g., calcium transients and beating) were investigated after 2 weeks of culture, revealing arrhythmia-like behavior in DCM tissue and highlighting functional hallmarks of the disease. Finally, the platform was validated using norepinephrine to assess the functional responsiveness of the tissues. These results demonstrate the potential of this system for disease modeling and future patient-specific investigations.

Indexed as

Cardiomyopathy, DilatedLab-On-A-Chip DevicesMyocardial ContractionCell DifferentiationCells, CulturedFibroblastsHumansInduced Pluripotent Stem CellsMicrophysiological SystemsMyocytes, CardiacTissue Engineeringdilated cardiomyopathydisease modelingdrug screeningheart‐on‐a‐chiphuman‐induced pluripotent stem cells (hiPSCs)

Identifiers

PMID42500934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.